Ubs Group Ag Alnylam Pharmaceuticals, Inc. Put Options Transaction History

Ubs Group Ag

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $372,606 - $642,200	-2,600 Reduced 9.45%	24,900 $6.05 Million
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $1.9 Million - $2.58 Million	13,000 Added 89.66%	27,500 $4.11 Million
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $1.47 Million - $1.91 Million	9,700 Added 202.08%	14,500 $2.78 Million
Q3 2023 Nov 09, 2023	BUY	$170.77 - $211.65 $819,696 - $1.02 Million	4,800 New	4,800 $850,000
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $3.28 Million - $5.35 Million	45,200	45,200 $5.31 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.